Clinical trials: Oral Cavity
Nutrition Support
Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation
The objective of this study is to assess the safety and efficacy of Oliclinomel N4 compared to compounded ternary parenteral nutrition (PN) admixtures for the delivery of PN in hospitalized adults for whom oral or enteral…
- Trial name
- NCT01579097
- Testing
- Oliclinomel N4, Compounded ternary parenteral nutrition admixtures
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Baxter Healthcare Corporation
Healthy
To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305
The purpose of this study is to learn more about how AZD1305 is handled by the body, i.e the absorption, distribution, metabolism and excretion of AZD1305.
- Trial name
- NCT00689247
- Testing
- AZD1305
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Weight Loss
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735…
- Trial name
- NCT06828055
- Testing
- VK2735
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Viking Therapeutics, Inc.
Contraception
Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive
This is an open-label, single treatment study. All subjects will receive one year of oral contraceptive therapy with DR-1011. Study participants will receive physical and gynecological exams, including Pap smear.
- Trial name
- NCT00196326
- Testing
- DR-1011
- Where
- 55 sites in United States
- Volunteers
- 2,235 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Healthy
Safety and Tolerability of Lu AF95245 in Healthy Young Men
The purpose of this study is to investigate the safety and tolerability of Lu AF95245 and what the body does to Lu AF95245 after swallowing single doses of the drug
- Trial name
- NCT04199585
- Testing
- Lu AF95245, Lu AF95245 14C radiolabelled spiked dosage
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Asthma
Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose)
Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction.
- Trial name
- NCT01743768
- Testing
- SB010
- Where
- 7 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Chronic Spontaneous Urticaria
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS-3095 oral administration in healthy subjects.
- Trial name
- NCT07230418
- Testing
- HRS-3095 Tablet
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04537637)
- Testing
- Oral Semaglutide
- Where
- 2 sites in Denmark
- Volunteers
- 99 people
- Sponsor
- Novo Nordisk A/S
Pain
Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers
This study evaluates the analgesic effect of Omnitram and tramadol during concurrent administration of paroxetine. Paroxetine administration is expected to diminish the analgesic effect of tramadol, but not Omnitram.
- Trial name
- NCT03312777
- Testing
- Omnitram, Tramadol
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Syntrix Biosystems, Inc.
EPP, XLP
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
To evaluate the long-term safety and tolerability of oral dersimelagon.
- Trial name
- NCT05005975
- Testing
- MT-7117
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 286 people
- Sponsor
- Tanabe Pharma America, Inc.
Glioblastoma, MGMT-Unmethylated Glioblastoma
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase…
- Trial name
- NCT03250299
- Testing
- Microtubule-Targeted Agent BAL101553, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Basilea Pharmaceutica
Healthy
A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood
The main objective of Trial Parts 1 and 2 is to investigate the relative bioavailability of two tablet strengths (low dose and high dose) of the intended Commercial Formulation of BI 730357 (Test, T) versus with the corresponding…
- Trial name
- NCT03886272
- Testing
- BI 730357 (Test), BI 730357 (Reference)
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Follicular Lymphoma (FL)
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all…
- Trial name
- EPCORE™FL-2 (NCT06191744)
- Testing
- Epcoritamab, Prednisone, Rituximab
- Where
- 266 sites in United States, Australia and 30 more
- Volunteers
- 1,095 people
- Sponsor
- Genmab
Advanced Solid Tumors
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
Panobinostat (LBH589) is a deacetylase inhibitor (DACi) which belongs to a structurally novel cinnamic hydroxamic acid class of compounds.
- Trial name
- NCT00997399
- Testing
- panobinostat (LBH589)
- Where
- 5 sites in United States, Netherlands and 2 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis (PsO)
Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients
The goal of this clinical trial] is to learn if SFA002 can treat mild, moderate and severe plaque psoriasis as good or better than Otezla, compared to placebo in adult and pediatric patients.
- Trial name
- NCT06863493
- Testing
- SFA002, Otezla
- Volunteers
- 125 people
- Sponsor
- SFA Therapeutics
Sickle Cell Disease
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine).
- Trial name
- ASCENT1 (NCT05405114)
- Testing
- NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea
- Where
- 118 sites in United States, Canada and 12 more
- Volunteers
- 96 people
- Sponsor
- Novo Nordisk A/S
Healthy
Binding of Lu AG06466 in the Brain in Healthy Men
A study to learn how Lu AG06466 and one of its break down products binds in the brain after single and repeated dosing
- Trial name
- NCT04419636
- Testing
- Lu AG06466
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Diabetes Mellitus Type 2
A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
- Trial name
- NCT00282971
- Testing
- Inhaled Insulin (Exubera), Standard of Care
- Where
- 64 sites in Canada, France and 5 more
- Volunteers
- 354 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and…
- Trial name
- NCT01121575
- Testing
- PF-02341066, PF-00299804
- Where
- 10 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Pfizer
Bioequivalence
Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
This is an open-label, randomized, single-center, single-dose, two-treatment, two-sequence, two-period, crossover, comparative study, where each subject will be randomly assigned to the reference or the test formulation in each…
- Trial name
- NCT03616301
- Testing
- Clavamox, Augmentin®
- Where
- Russia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Pharmtechnology LLC